Member Info for mathsprof

I think it may be the - (dash) in the form means "not filled in" rather than zero. His holding is reported as <3% not 0%.

I suspect he has sold part of his holding and in all probability we'll never know any more.

Uncanny.
401 - no patients lived 300 days longer. The trial was supposed to last 6 months, but all patients had died well before that. Go back and read the data from the 7 patients.

The new shares won't have been formally issued yet so aren't in the total. And the RNS states acquisition or disposal.

I'm afraid they are likely to be very well aware of it, and were so desperate to raise fiance that it wouldn't matter to them.

If the alternative was a placing at 0.3p, what might you do? Especially if you can get your wages paid fo 2 years in one go ,and you don't have any regard for the SP or the second-hand shareholders.

Perhaps we have the best deal in the circumstances. The BOD tried it with Bracknor, but the action group at the time forced them to stop it. The result either way as we now know was the SP collapsing further from 9p (Bracknor) to 6p (action group) down to 1p in Sep 17 before the miracle recovery. Now down further to 0.6p, 0.4p and where next?

They have got to sell their 3x71m shares first. The point of the extra fee clause is to counter any fall in SP from 0.6p.

Say they sell at 0.4p and the SP also settles at this point on June 21 (ie 33% down), there will be a break fee or first payment reduction of £333k, reducing effectively the proceeds of the subscription tranches from £1m to £667k. This effectively means that the price they are paying for each share is 0.4p not 0.6p (excluding the effect of the £278k fee).

So it doesn't matter to EHGO what price they sell at, provided the SP is approx the same or lower on June 21. Then after that the death spiral starts, but there might be news in Q3 on the 201 front to cheer us up.

Who are these people? They are almost invisible on the internet - linkdn show a website with a broken link, and a parent company that is equally illusive.

I think the time to come back to VAL is after the next consolidation, after the EHGO dilutions are all over and their overhang is gone, and if the mcap is still under £4m.

Otherwise I'm now staying out, having sold out earlier in the month.

It's not today's bottom price that matters. It's the end of next week, and then the end of May, and then . . .
All we're left with is a fart.

How is this a fact? How do you know that money will last until after prelim results? I think you are expressing an opinion.

Yes, you're missing my contract note for a 45k buy at 5.5p! I had to double check it after your first post on this thread, to make sure I really had made a purchase.

I've been patiently waiting for the ask to drop below 5.57p for the last week. After the 2 sells below 5.5p I wondered whether the price would collapse further (eg big sell going through), but was happy to take the 45k on offer at 5.5p since larger amounts were quoted at 5.65p

Correction (ie my guess):

Buys 336k
Sells 66k

Uncanny - it may be soon we will know about 401, but that's not the same as money coming soon. That's the way I understand it, anyway.

And my thanks too.

But I don't think you implied any timescale for when cash might come from 401. It may finance 101 201 301, but probably not in the near future. There may even be a 501 by then, too.

Can't see how these automation graphs will help the like of you or me understand anything to do with cancerous mutations. Sorry. It looks a very specialist subject.

From what I understand, there is no more data at present. And therein lies the problem with 401. And the long wait.

Geecee3 - agreed. I was simply quoting figures given by Valiseek in a presentation which gave a pre-investment valuation of Valiseek at £4.9m. (Nov 2017)

Valirx is now a third party to 401, simply a shareholder in Valiseek.

Valiseek will need a fund raise, but Valirx may well not. If the JV involves issuing shares to new partners, then Val's slice is diluted. Valirx does not appear to be selling, and I can't see any immediate money coming into Val's coffers. So its at least a 3 year wait for any revenue.

It also depends on what the phrase co-financing means.

I'm assuming that Valiseek and partners will between than contribute £20m and Valiseek will issue new shares to the co-partners. There may be other models.

Noise - the loan to Valiseek was £160k.

In the Nov 2017 presentation Valiseek was valued at £4.9m, so Val's slice was £2.7m. If we are going to get a Fund-raise for Valiseek, either Val's slice will be severely diluted or Val will have to cough up a substantial amount. The funding cost over three years was projected to be around £20m, which would leave us owning a mere 11% of Valiseek if Val contributes nothing.

So I think we can see why market reaction is muted.

It was yesterday, but does that make any difference?

Yes I am for buying small amounts. But strangely getting a higher quote to sell the same amount.